Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCEED-BHS3: Evolocumab + Empagliflozin in T2DM
NCT03932721Phase 4Completed
- Sponsor
- Universidade Estadual de Campinas
- Start
- Oct 2018
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evolocumab in dyslipidemia and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Universidade Estadual de Campinas. Primary endpoint: Flow Mediated Dilation at 16 weeks. Started Oct 2018; status: completed.
02
Drugs
evolocumab
03
Conditions
dyslipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03932721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932721.